ReviewEfficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Under a Creative Commons license
open access
Keywords
Breast cancer
Human epidermal growth factor receptor
Lapatinib
Targeted therapy
Trastuzumab
Abbreviations
AMP
adenosine monophosphate
CBR
clinical benefit rate
CI
confidence interval
CR
complete response
EGFR
epidermal growth factor receptor
ER
estrogen receptor
FISH
fluorescent in situ hybridization
HER
human epidermal growth factor receptor
HR
hazard ratio
IHC
immunohistochemistry
LVEF
left ventricular ejection fraction
MAPK
mitogen-activated protein kinases
MBC
metastatic breast cancer
mTOR
mammalian target of rapamycin
pCR
pathological complete response
PFS
progression free survival
PI3K
phosphatidylinositol 3-kinase
PR
partial response
SD
stable disease
TGFα
transforming growth factor α
TKI
tyrosine kinase inhibitor
TTP
time to progression
OS
overall survival
Cited by (0)
Copyright © 2012 Elsevier Ltd. All rights reserved.